Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

AXL inhibitor

DRUG CLASS:

AXL inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

AXL positive	Non Small Cell Lung Cancer	AXL positive	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2
GAS6 elevation	Ovarian Cancer	GAS6 elevation	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
GAS6 overexpression	Ovarian Cancer	GAS6 overexpression	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
SLFN11 expression	Myelodysplastic Syndrome	SLFN11 expression	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Myelodysplastic Syndrome	ANG elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3